Stockreport

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]

GRI Bio, Inc.  (GRI) 
PDF a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024 [Read more]